Description: Ceftobiprole (Ro-63-9141; BAL 9141) is a fifth-generation and broad-spectrum cephalosporin prodrug for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae, to penicillin-binding protein 2x in Streptococcus pneumoniae, and to penicillin-binding protein 5 in Enterococcus faecalis.

References:

[3]. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015 Aug 18;9:4565-72. doi: 10.2147/DDDT.S56616. eCollection 2015.

纯度：≥98%

CAS：209467-52-7